Skip to content

Mindfulness-based stress reduction to improve depression, pain and high patient global assessment in controlled rheumatoid arthritis.

Isabelle Gaboury, Patricia L Dobkin, Françoise Gendron, Pasquale Roberge, Marie-Claude Beaulieu, Nathalie Carrier, Pierre Dagenais, Sophie Roux, Gilles Boire

Rheumatology advances in practice 2022 DOI: 10.1093/rap/rkac074 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Pragmatic pilot study Qualitative Peer reviewed
Sample size 28
Population Rheumatoid arthritis patients with clinically controlled inflammation and high depression scores (CES-D ≥16) and/or patient general assessment at least 2/10 higher than evaluator general assessment
Intervention Mindfulness-based stress reduction (MBSR)
Duration 12-month follow-up
Measures CES-D, PGA, modified HAQ, SDAI, GAD-7, CHIP, sleep disturbance and pain
Topics Depression Meditation
Keywords Coping Function Mindfulness-based stress reduction Pain Patient general assessment Remission
Key points Among patients who completed MBSR, anxiety, depression, emotion-oriented coping, sleep, and function significantly improved up to 12 months later, while pain, patient global assessment, the patient-evaluator gap, and disease activity index showed no significant change. The authors suggest larger studies are needed to evaluate MBSR's weaker impact on RA-related pain and patient global assessment.

Abstract

The aim was to improve distressing patient-reported outcomes (PROs) that persisted in RA patients with clinically controlled inflammation (controlled RA). In a pragmatic pilot study, we offered mindfulness-based stress reduction (MBSR), a group intervention, to controlled RA patients who had high (≥16) Centre for Evaluation Studies depression (CES-D) scores and/or patient general assessment of disease activity (PGA) at least 2/10 larger than evaluator general assessment (EGA) (PGA-EGA: Delta). Evaluations before, 6 and 12 months after MBSR included CES-D, PGA, modified HAQ, simple disease activity index (SDAI), anxiety (general anxiety disorder 7; GAD-7), coping strategies (coping with health injuries and problems; CHIP), sleep disturbance and pain. Facilitators and obstacles to recruitment and participation were identified. A subset of patients was interviewed for qualitative analysis of their experience. Out of 306 screened patients, 65 were referred, 39 (60%) agreed and 28 (43%) completed MBSR. Anticipated burden, timing and frequency of group meetings, commuting issues, age extremes and co-morbidities were barriers to participation. Up to 12 months after MBSR, anxiety, depression, emotion-oriented coping, sleep and function significantly improved. Nonetheless, no significant impact was observed on pain, PGA, Delta or SDAI. The interviews revealed that benefits, including integration of effective coping strategies, were maintained. We addressed MBSR feasibility issues and selection of outcomes in controlled RA patients with distressing PROs. For patients who chose to participate in MBSR, lasting benefits were evident for anxiety, depression, sleep and function. Larger studies are required to evaluate the weaker impact of MBSR on RA-related pain and PGA.

Comparable studies

Other non-randomized and open-label trials on depression, most cited first.

Study Year Design Participants
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression 2016 Open-label feasibility trial n = 12
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression 2017 Open-label trial n = 20
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression Patients with recurrent depression 2015 Open-label trial n = 17

Citations in the library

Explore topics